Transient suppression of ovulatory ovarian function in pony mares after treatment with slow-release deslorelin implants

Kapš, Miroslav; Okada, Carolina Tiemi Cardoso; Gautier, Camille; Aurich, Jörg; Scarlet, D.; Kuhl, Juliane; Aurich, Christine

doi:10.1016/j.domaniend.2020.106505

Cited by 6 publications

(15 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study was approved by the Austrian Federal Ministry for Science and Research (animal experimentation permit numbers BMWFW-68.205/0065-V/3b/2018 and BMBWF-68.205/0113-V/3b/2019) and was conducted in Vienna, Austria (longitude 16.4 ) starting in April. The experiment followed a protocol recently established in Shetland pony mares [9]. Before the start of the experiment, mares were regularly examined by transrectal ultrasonography to ensure physiological cyclic ovarian activity.…”

Section: Experimental Designmentioning

confidence: 99%

“…The progesterone concentration in plasma was determined with an enzyme-linked immunosorbent assay (Demeditec Progesterone ELISA kit, Demeditec Diagnostics, Kiel, Germany) as described [9]. Plasma was always diluted 1:100 before analysis.…”

Section: Endocrine Analysesmentioning

confidence: 99%

“…Concentrations of FSH were determined using a previously validated RIA [23], with slight modifications as described [9]. The sensitivity of the assay was 0.5 ng/mL and the intra-and inter-assay coefficients of variation were 4.1% and 5.4%, respectively.…”

Section: Endocrine Analysesmentioning

confidence: 99%

“…In response, pulsatile gonadotrophin secretion ceases and sexual function may be suppressed but pronounced species differences have been determined (reviewed by Goericke-Pesch 2017 [7]). Although the sensitivity of horses to down-regulation of pituitary GnRH receptors has been questioned [8], a successful suppression of estrus and estrous behavior in association with a transient inhibition of ovarian activity after treatment of Shetland pony mares with SRI deslorelin implants has recently been demonstrated [9]. The mean interval from SRI injection to the first ovulation was close to 40 days with a 4.7 mg deslorelin SRI and 60 days with a 9.4 mg deslorelin SRI in comparison to 20 days in untreated controls.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Deslorelin Slow-Release Implants Delay Ovulation and Increase Plasma AMH Concentration and Small Antral Follicles in Haflinger Mares

Kapš

Okada

Gautier

et al. 2021

Animals

View full text Add to dashboard Cite

There is an increasing interest in the manipulation of ovarian follicular populations in large domestic animals because this could prove beneficial for assisted reproductive techniques such as ovum pick-up (OPU). The aim of the present study was to evaluate the effects of deslorelin slow-release implants (SRI) on the interovulatory interval, antral follicle count (AFC), number of follicles of different size ranges and plasma anti-Muellerian hormone (AMH) concentration in mares. To synchronize their estrous cycles, Haflinger mares (n = 12) were treated twice with a PGF2α analogue. One day after the second injection (day 0), mares received a 9.4 mg deslorelin SRI (group DES, n = 6) or 1.25 mg deslorelin in a short-acting formulation (CON; n = 6), respectively. Regular transrectal ultrasonography of the genital tract was performed and blood samples were collected for the analysis of progesterone, AMH and gonadotrophins. The interval from implant insertion to the first spontaneous ovulation was 23.8 ± 10.5 days in group DES compared to 17.0 ± 3.9 days in group CON (p < 0.05). For the concentrations of LH, FSH and AMH, interactions between time and treatment were detected (p < 0.05). The AFC and the mean number of follicles with 5 to 10, 10 to 15 and 15 to 20 mm in diameter changed over time (p < 0.05). A time x treatment interaction was demonstrated for follicles of 10 to 15 mm in diameter (p < 0.05). The changes in this follicular subpopulation were reflected by increased plasma AMH concentration in group DES. In conclusion, 9.4 mg deslorelin implants show minor effects with regard to estrus suppression in mares, whereas the changes in the subpopulation of small ovarian follicles could be a promising tool for preparation of mares for OPU.

show abstract

Section: Experimental Designmentioning

confidence: 99%

Section: Endocrine Analysesmentioning

confidence: 99%

Section: Endocrine Analysesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Deslorelin Slow-Release Implants Delay Ovulation and Increase Plasma AMH Concentration and Small Antral Follicles in Haflinger Mares

Kapš

Okada

Gautier

et al. 2021

Animals

View full text Add to dashboard Cite

show abstract

“…Anecdotally the more concentrated form, marketed for dogs and ferrets as Suprelorin 10 (4.7 mg deslorelin acetate), has been used clinically off-licence. Recently Kaps et al (2021) published a study looking at down-regulation of pituitary GnRH receptors and subsequent inhibition of ovulation and oestrus behaviour in Shetland mares using one or two 4.7 mg Suprelorin 10 implants. There was a transient inhibition of ovulation which was approximately equivalent to one and two oestrous cycles for the 4.7 mg (one implant) and 9.5 mg (two implant) groups, respectively.…”

Section: Suppression Of Ovarian Activity Through Suppression Of Gnrhmentioning

confidence: 99%

A review of oestrus suppression techniques in mares

Crabtree

2020

Equine Veterinary Education

View full text Add to dashboard Cite

Many fillies and mares are accused of behaving badly by their owners or trainers, and their reproductive hormones and ovaries are commonly blamed for this. Overt oestrus behaviour, however natural, is undesirable when a horse is being ridden, trained and competed. More subtle behaviours may be attributed to the reproductive cycle and presented as the cause of poor performance in the elite competition mare. Sometimes behaviours are complex, perhaps at odds with what one expects for normal reproductive behaviour and in many cases may not be associated with the reproductive cycle at all, rather associated with pain of musculoskeletal or soft tissue origin. The situation represents a diagnostic dilemma to positively associate undesirable behaviours with the ovarian hormones or ovarian pain, before an attempt can be made to modify the behaviour through the suppression of oestrus. This article will review the reasons for presentation, the behavioural patterns of the reproductive cycle and the diagnosis of reproductive behavioural problems. The range of techniques for oestrus suppression will be reviewed along with their clinical application and any known current regulatory issues associated with their use.

show abstract

Altrenogest treatment reduces the stress response of three-year-old warmblood mares during their initial equestrian training

Kapš

Lutzer²,

Gautier

et al. 2022

Domestic Animal Endocrinology

View full text Add to dashboard Cite

Transient suppression of ovulatory ovarian function in pony mares after treatment with slow-release deslorelin implants

Cited by 6 publications

References 32 publications

Deslorelin Slow-Release Implants Delay Ovulation and Increase Plasma AMH Concentration and Small Antral Follicles in Haflinger Mares

Deslorelin Slow-Release Implants Delay Ovulation and Increase Plasma AMH Concentration and Small Antral Follicles in Haflinger Mares

A review of oestrus suppression techniques in mares

Altrenogest treatment reduces the stress response of three-year-old warmblood mares during their initial equestrian training

Contact Info

Product

Resources

About